Document is current
Any future updates will be listed below
-
Authors
Tsuchiya, Haruka
Ota, Mineto
Takahashi, Haruka
Hatano, Hiroaki
Ogawa, Megumi
Nakajima, Sotaro
Yoshihara, Risa
Okamura, Tomohisa
Sumitomo, Shuji
Fujio, Keishi https://orcid.org/0000-0001-7276-5254
-
Funding
Funding for this research was provided by:
Eli Lilly Japan
AbbVie
- License Information
-
More Information
Article History
Received: 11 April 2024
Accepted: 15 May 2024
First Online: 4 June 2024
Declarations
:
: This study was approved by the Ethics Committees of the University of Tokyo (G3582).
: Not applicable.
: M. Ota, H.H., and T.O. belong to the Social Cooperation Programme, Department of Functional Genomics and Immunological Diseases, supported by Chugai Pharmaceutical. K.F. receives consulting honoraria, research support, and speaking fees from Chugai Pharmaceutical. K.F. receives research support and speaking fees from Eli Lilly Japan K.K. and AbbVie GK. K.F. receives speaking fees from Pfizer Japan Inc. H. Tsuchiya. receives speaking fees from Chugai Pharmaceutical, Eli Lilly Japan K.K. and AbbVie GK. S.S. receives speaking fees from Chugai Pharmaceutical, AbbVie GK, and Pfizer Japan Inc. K.F. is an Editor of <i>Inflammation and Regeneration</i>.
